Company news

Revolution Medicines, Inc. news in 2022

Revolution Medicines, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor

December 18, 2022

Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration

December 6, 2022

Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress

November 6, 2022

Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022

October 31, 2022

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor

September 21, 2022

Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire

August 31, 2022

Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress

August 8, 2022

Revolution Medicines to Report Financial Results for Second Quarter 2022 After Market Close on August 9, 2022

July 27, 2022

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

July 21, 2022

Revolution Medicines Announces Pricing of Upsized $230.0 Million Public Offering of Common Stock

July 18, 2022

Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors

July 12, 2022

Revolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of RMC-6236

June 27, 2022

Revolution Medicines to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference

June 8, 2022

Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress

May 8, 2022

Revolution Medicines to Report Financial Results for First Quarter 2022 After Market Close on May 9, 2022

April 20, 2022

Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2022

March 8, 2022

Revolution Medicines to Participate in Cowen 42nd Annual Health Care Conference

February 28, 2022

Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress

February 27, 2022

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2021 After Market Close on February 28, 2022

February 21, 2022

Revolution Medicines to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference

February 2, 2022

Revolution Medicines Reports Progress Across Pipeline of Targeted Therapeutics for RAS-Addicted Cancers in Presentation at 40th Annual J.P. Morgan Healthcare Conference

January 10, 2022

Revolution Medicines to Provide R&D Update, Including Expansion of Development-Stage RAS(ON) Inhibitor Pipeline, During Presentation at 40th Annual J.P. Morgan Healthcare Conference

January 3, 2022

Calls in 2022

Decks in 2022